Multitargeted anti-infective drugs : resilience to resistance in the antimicrobial resistance era

Suckling, Colin J and Hunter, Iain S and Scott, Fraser J (2022) Multitargeted anti-infective drugs : resilience to resistance in the antimicrobial resistance era. Future Drug Discovery, 4 (1). ISSN 2631-3316 (https://doi.org/10.4155/fdd-2022-0001)

[thumbnail of Scott-etal-FDD-2022-Multi-targeted-anti-infective-drugs-resilience-to-resistance]
Preview
 Text. Filename: Scott_etal_FDD_2022_Multi_targeted_anti_infective_drugs_resilience_to_resistance.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (3MB)| Preview

Abstract

The standard drug discovery paradigm of single molecule - single biological target - single biological effect is perhaps particularly unsuitable for anti-infective drug discovery. This is due to the rapid evolution of resistance likely to be observed with single target drugs. Multi-targeted anti-infective drugs (MTAIDs) are likely to be superior due to their lower susceptibility to target-related resistance mechanisms. Strathclyde Minor Groove Binders (S-MGBs) are a class of compounds which have been developed by adopting the MTAID paradigm, and their effectiveness against a wide range of pathogenic organisms is discussed. The renaming of this class to Strathclyde Nucleic Acid Binders (SNABs) is also presented due to their likely targets including both DNA and RNA.

CORE (COnnecting REpositories)